X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-01-07 | ZBIO | Zenas Biopharma, Inc. | Moulder Leon O Jr | CEO | P - Purchase | $16.39 | +100,000 | 2,075,122 | +5% | +$1,639,000 | |||||
2026-01-08 | MNKD | Mannkind Corp | Tross Stuart A | Chief People, Workpl Officer | S - Sale | $6.33 | -47,006 | 985,007 | -5% | -$297,548 | ||||||
| D | 2026-01-07 | NAMS | Newamsterdam Pharma Co N.V. | Davidson Michael H. | CEO | S - Sale+OE | $0.00 | -11,582 | 459,859 | -2% | -$0 | |||||
| D | 2026-01-08 | ANAB | Anaptysbio, Inc | Lizzul Paul F. | Chief Medical Officer | S - Sale+OE | $44.71 | -3,650 | 42,088 | -8% | -$163,192 | |||||
| D | 2026-01-08 | ANAB | Anaptysbio, Inc | Mulroy Dennis | CFO | S - Sale+OE | $44.71 | -2,515 | 21,852 | -10% | -$112,446 | |||||
| D | 2026-01-08 | ANAB | Anaptysbio, Inc | Loumeau Eric J | GC | S - Sale+OE | $44.71 | -2,210 | 12,835 | -15% | -$98,809 | |||||
| D | 2026-01-08 | ANAB | Anaptysbio, Inc | Faga Daniel | Pres, CEO | S - Sale+OE | $44.71 | -14,281 | 479,344 | -3% | -$638,504 | |||||
| D | 2026-01-08 | ARDX | Ardelyx, Inc. | Williams Laura A | Chief Patient Officer | S - Sale+OE | $6.98 | -50,000 | 361,563 | -12% | -$348,900 | |||||
| D | 2026-01-08 | EQ | Equillium, Inc. | Tom Penny | Principal Accounting Officer | S - Sale+OE | $1.29 | -6,533 | 0 | -100% | -$8,428 | |||||
2026-01-08 | XERS | Xeris Biopharma Holdings, Inc. | McCulloch Kevin | See Remarks | S - Sale | $8.00 | -15,000 | 1,710,426 | -1% | -$120,000 | ||||||
| D | 2026-01-07 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale+OE | $331.76 | -664 | 223,106 | 0% | -$220,289 | |||||
2026-01-07 | RNA | Avidity Biosciences, Inc. | Boyce Sarah | Pres, CEO | S - Sale | $72.23 | -8,576 | 283,394 | -3% | -$619,444 | ||||||
2026-01-07 | RNA | Avidity Biosciences, Inc. | Calderaro Charles III | Chief Technical Officer | S - Sale | $72.23 | -3,727 | 49,797 | -7% | -$269,201 | ||||||
2026-01-07 | RNA | Avidity Biosciences, Inc. | McCarthy Teresa | CHRO | S - Sale | $72.23 | -1,965 | 116,867 | -2% | -$141,932 | ||||||
2026-01-07 | RNA | Avidity Biosciences, Inc. | Moriarty John B | GC | S - Sale | $72.23 | -2,374 | 74,557 | -3% | -$171,474 | ||||||
2026-01-07 | RNA | Avidity Biosciences, Inc. | Maclean Michael F | CFO | S - Sale | $72.23 | -1,974 | 63,832 | -3% | -$142,582 | ||||||
2026-01-07 | RNA | Avidity Biosciences, Inc. | Hughes Steven George | Chief Medical Officer | S - Sale | $72.23 | -2,373 | 36,494 | -6% | -$171,402 | ||||||
2026-01-07 | RNA | Avidity Biosciences, Inc. | Flanagan W. Michael | Chief Scientific Officer | S - Sale | $72.23 | -2,373 | 91,627 | -3% | -$171,402 | ||||||
| D | 2026-01-07 | IONS | Ionis Pharmaceuticals Inc | Devers Shannon L. | EVP, Chief HR Ofc | S - Sale+OE | $85.08 | -44,199 | 17,494 | -72% | -$3,760,577 | |||||
| M | 2026-01-07 | MIST | Milestone Pharmaceuticals Inc. | Oliveto Joseph | Pres, CEO | S - Sale | $2.25 | -43,500 | 303,721 | -13% | -$97,875 | |||||
2026-01-08 | KNSA | Kiniksa Pharmaceuticals International, Plc | Ragosa Mark | CFO | S - Sale | $41.89 | -12,000 | 19,086 | -39% | -$502,680 | ||||||
2026-01-08 | ALT | Altimmune, Inc. | Pisano Wayne | Dir | P - Purchase | $4.08 | +5,000 | 13,498 | +59% | +$20,410 | ||||||
2026-01-07 | VRTX | Vertex Pharmaceuticals Inc / Ma | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $474.99 | -4,500 | 42,293 | -10% | -$2,137,455 | ||||||
| D | 2026-01-08 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $2.69 | -13,000 | 0 | -100% | -$34,953 | |||||
| D | 2026-01-07 | ERAS | Erasca, Inc. | Garner Ebun | GC, Corp. Sec. | S - Sale+OE | $5.59 | -120,000 | 25,076 | -83% | -$670,812 | |||||
2026-01-07 | XCUR | Exicure, Inc. | Exicure Hitron Inc. | 10% | S - Sale | $4.50 | -741,272 | 5,925,394 | -11% | -$3,335,724 | ||||||
| D | 2026-01-06 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $35.18 | -20,000 | 1,235 | -94% | -$703,656 | |||||
| M | 2026-01-06 | PBYI | Puma Biotechnology, Inc. | Auerbach Alan H | Pres, CEO, 10% | S - Sale | $5.86 | -34,950 | 7,145,951 | 0% | -$204,878 | |||||
| M | 2026-01-06 | PBYI | Puma Biotechnology, Inc. | Hunt Douglas M | See Remarks | S - Sale | $5.86 | -8,987 | 155,907 | -5% | -$52,696 | |||||
| M | 2026-01-06 | PBYI | Puma Biotechnology, Inc. | Nougues Maximo F | CFO | S - Sale | $5.86 | -10,945 | 193,284 | -5% | -$64,187 | |||||
2026-01-07 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale | $40.09 | -328 | 55,712 | -1% | -$13,149 | ||||||
| D | 2026-01-08 | ALKS | Alkermes Plc. | Hopkinson Craig C. | EVP R, D, Chief Medical Office | S - Sale+OE | $30.00 | -5,000 | 61,740 | -7% | -$150,005 | |||||
| M | 2026-01-06 | INSM | Insmed Inc | Adsett Roger | COO | S - Sale | $174.06 | -4,290 | 107,601 | -4% | -$746,711 | |||||
| M | 2026-01-06 | INSM | Insmed Inc | Bonstein Sara | CFO | S - Sale | $174.22 | -4,642 | 80,506 | -5% | -$808,733 | |||||
| DM | 2026-01-06 | INSM | Insmed Inc | Flammer Martina M.D. | Chief Medical Officer | S - Sale+OE | $174.06 | -16,530 | 86,794 | -16% | -$2,877,139 | |||||
| M | 2026-01-06 | PTCT | Ptc Therapeutics, Inc. | Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER | S - Sale | $77.19 | -2,616 | 73,727 | -3% | -$201,919 | |||||
2026-01-06 | PTCT | Ptc Therapeutics, Inc. | Gravier Pierre | CFO | S - Sale | $76.95 | -2,139 | 90,310 | -2% | -$164,596 | ||||||
| M | 2026-01-06 | PTCT | Ptc Therapeutics, Inc. | Pauwels Eric | CHIEF BUSINESS OFFICER | S - Sale | $77.18 | -3,141 | 87,489 | -3% | -$242,417 | |||||
| M | 2026-01-06 | PTCT | Ptc Therapeutics, Inc. | Klein Matthew B. | CEO | S - Sale | $77.15 | -8,165 | 396,967 | -2% | -$629,895 | |||||
| M | 2026-01-06 | PTCT | Ptc Therapeutics, Inc. | Golden Lee Scott | EVP, CHIEF MEDICAL OFFICER | S - Sale | $77.12 | -1,982 | 93,294 | -2% | -$152,855 | |||||
| M | 2026-01-06 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale | $174.03 | -9,676 | 599,831 | -2% | -$1,683,950 | |||||
| DM | 2026-01-06 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $77.31 | -6,618 | 117,659 | -5% | -$511,641 | |||||
| M | 2026-01-06 | PTCT | Ptc Therapeutics, Inc. | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | S - Sale | $77.19 | -2,411 | 122,927 | -2% | -$186,098 | |||||
| M | 2026-01-06 | INSM | Insmed Inc | Smith Michael Alexander | GC | S - Sale | $174.00 | -3,158 | 57,037 | -5% | -$549,494 | |||||
2025-12-31 | ZNTL | Zentalis Pharmaceuticals, Inc. | Walters Group | 10% | P - Purchase | $1.20 | +6,459,973 | 13,509,973 | +92% | +$7,751,968 | ||||||
2026-01-06 | RNAC | Cartesian Therapeutics, Inc. | Brunn Carsten | Pres, CEO | S - Sale | $6.82 | -23,766 | 323,530 | -7% | -$162,077 | ||||||
2026-01-06 | RNAC | Cartesian Therapeutics, Inc. | Miljkovic Milos | Chief Medical Officer | S - Sale | $6.82 | -3,573 | 58,820 | -6% | -$24,367 | ||||||
2026-01-06 | RNAC | Cartesian Therapeutics, Inc. | Davis Blaine | CFO | S - Sale | $6.82 | -10,591 | 121,220 | -8% | -$72,227 | ||||||
| D | 2026-01-07 | ANAB | Anaptysbio, Inc | Loumeau Eric J | GC | S - Sale+OE | $45.56 | -9,639 | 9,157 | -51% | -$439,200 | |||||
| D | 2026-01-07 | ANAB | Anaptysbio, Inc | Lizzul Paul F. | Chief Medical Officer | S - Sale+OE | $45.11 | -2,235 | 37,213 | -6% | -$100,821 | |||||
| D | 2026-01-07 | ANAB | Anaptysbio, Inc | Faga Daniel | Pres, CEO | S - Sale+OE | $45.11 | -9,202 | 466,787 | -2% | -$415,102 | |||||
| D | 2026-01-07 | ANAB | Anaptysbio, Inc | Mulroy Dennis | CFO | S - Sale+OE | $45.11 | -1,908 | 17,667 | -10% | -$86,070 | |||||
| AM | 2025-11-25 | CVRX | Cvrx, Inc. | Johnson & Johnson | 10% | S - Sale | $10.03 | -22,337 | 4,024,861 | -1% | -$224,040 | |||||
2026-01-06 | HROW | Harrow, Inc. | Opaleye Management Inc. | 10% | S - Sale | $53.35 | -20,000 | 3,885,000 | -1% | -$1,066,914 | ||||||
2026-01-06 | AMLX | Amylyx Pharmaceuticals, Inc. | Frates James M | CFO | S - Sale | $11.11 | -3,326 | 303,635 | -1% | -$36,954 | ||||||
2026-01-06 | AMLX | Amylyx Pharmaceuticals, Inc. | Cohen Joshua B | Co-CEO | S - Sale | $11.09 | -7,715 | 3,317,632 | 0% | -$85,596 | ||||||
2026-01-06 | AMLX | Amylyx Pharmaceuticals, Inc. | Klee Justin B. | Co-CEO | S - Sale | $11.09 | -7,715 | 3,317,586 | 0% | -$85,589 | ||||||
| D | 2026-01-06 | VRTX | Vertex Pharmaceuticals Inc / Ma | Wagner Charles F Jr | EVP, CO, FO | S - Sale+OE | $461.00 | -9,532 | 37,725 | -20% | -$4,394,252 | |||||
| D | 2026-01-07 | REGN | Regeneron Pharmaceuticals, Inc. | Bassler Bonnie L | Dir | S - Sale+OE | $800.00 | -1,500 | 1,703 | -47% | -$1,200,000 | |||||
| E | 2026-01-07 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $0.11 | -292,148 | 91,896,978 | 0% | -$33,045 | |||||
| M | 2026-01-05 | ANTX | An2 Therapeutics, Inc. | Day Lucy | CFO | S - Sale | $1.01 | -8,807 | 75,363 | -10% | -$8,883 | |||||
| M | 2026-01-05 | ANTX | An2 Therapeutics, Inc. | Prior Stephen David | Chief Strategy Officer | S - Sale | $1.01 | -6,462 | 59,086 | -10% | -$6,507 | |||||
| M | 2026-01-05 | ANTX | An2 Therapeutics, Inc. | Chanda Sanjay | Chief Development Officer | S - Sale | $1.01 | -9,251 | 75,823 | -11% | -$9,332 | |||||
| M | 2026-01-05 | ANTX | An2 Therapeutics, Inc. | Eizen Joshua M | See Remarks | S - Sale | $1.00 | -24,854 | 152,499 | -14% | -$24,962 | |||||
| DM | 2026-01-05 | AXSM | Axsome Therapeutics, Inc. | Tabuteau Herriot | CEO, 10% | S - Sale+OE | $171.30 | -139,414 | 7,351,729 | -2% | -$23,881,618 | |||||
| D | 2026-01-05 | NAMS | Newamsterdam Pharma Co N.V. | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | S - Sale+OE | $33.25 | -6,000 | 98,981 | -6% | -$199,500 | |||||
| D | 2026-01-05 | NAMS | Newamsterdam Pharma Co N.V. | Kooij Louise Frederika | Chief Accounting Officer | S - Sale+OE | $33.25 | -2,647 | 24,353 | -10% | -$88,013 | |||||
| D | 2026-01-05 | NAMS | Newamsterdam Pharma Co N.V. | Somaiya Mayur Ian | CFO | S - Sale+OE | $33.25 | -5,118 | 58,382 | -8% | -$170,174 | |||||
2026-01-05 | ARQT | Arcutis Biotherapeutics, Inc. | Burnett Patrick | See Remarks | S - Sale | $28.98 | -2,490 | 94,120 | -3% | -$72,166 | ||||||
| M | 2026-01-05 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% | S - Sale | $6.04 | -12,918 | 753,562 | -2% | -$78,011 | |||||
| DM | 2026-01-05 | NUVL | Nuvalent, Inc. | Pelish Henry E. | Chief Scientific Officer | S - Sale+OE | $97.24 | -5,160 | 83,388 | -6% | -$501,753 | |||||
| DM | 2026-01-05 | NUVL | Nuvalent, Inc. | Noci Darlene | Chief Development Officer | S - Sale+OE | $97.25 | -7,417 | 58,117 | -11% | -$721,320 | |||||
| DM | 2026-01-05 | NUVL | Nuvalent, Inc. | Miller Deborah Ann | GC | S - Sale+OE | $97.26 | -6,952 | 59,634 | -10% | -$676,158 | |||||
| DM | 2026-01-05 | NUVL | Nuvalent, Inc. | Turner Christopher Durant | Chief Medical Officer | S - Sale+OE | $97.25 | -7,417 | 72,630 | -9% | -$721,320 | |||||
| DM | 2026-01-05 | NUVL | Nuvalent, Inc. | Balcom Alexandra | CFO | S - Sale+OE | $97.25 | -7,417 | 99,233 | -7% | -$721,320 | |||||
| DM | 2026-01-05 | NUVL | Nuvalent, Inc. | Porter James Richard | Pres, CEO | S - Sale+OE | $97.26 | -27,433 | 324,879 | -8% | -$2,668,260 | |||||
| M | 2026-01-05 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $0.65 | -71,054 | 2,401,243 | -3% | -$45,882 | |||||
| D | 2026-01-05 | CRNX | Crinetics Pharmaceuticals, Inc. | Kalofonos Isabel | Chief Commercial Officer | S - Sale+OE | $55.00 | -2,500 | 834 | -75% | -$137,500 | |||||
2026-01-05 | CLYM | Climb Bio, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $3.50 | +7,111 | 11,300,939 | 0% | +$24,889 | ||||||
| D | 2026-01-05 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $487.38 | -14,625 | 2,648 | -85% | -$7,127,877 | |||||
| D | 2026-01-05 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $487.38 | -7,875 | 2,648 | -75% | -$3,838,085 | |||||
2026-01-06 | ALXO | Alx Oncology Holdings Inc | Pinto Shelly | SVP, Finance, CAO | S - Sale | $1.11 | -3,925 | 88,273 | -4% | -$4,357 | ||||||
| D | 2026-01-05 | AGIO | Agios Pharmaceuticals, Inc. | Milanova Tsveta | Chief Commercial Officer | S - Sale+OE | $27.02 | -2,872 | 34,793 | -8% | -$77,601 | |||||
2026-01-05 | RCUS | Arcus Biosciences, Inc. | Jaen Juan C. | Pres | S - Sale | $21.41 | -31,823 | 1,268,252 | -2% | -$681,342 | ||||||
| M | 2026-01-05 | TVTX | Travere Therapeutics, Inc. | Inrig Jula | Chief Medical Officer | S - Sale | $39.74 | -2,476 | 86,311 | -3% | -$98,404 | |||||
2026-01-05 | IRWD | Ironwood Pharmaceuticals Inc | Silver Ronald | Principal Accounting Officer | S - Sale | $4.60 | -35,416 | 276,809 | -11% | -$162,914 | ||||||
2026-01-05 | INDV | Indivior Plc | Ryan Barbara | Dir | P - Purchase | $35.39 | +775 | 1,963 | +65% | +$27,429 | ||||||
2026-01-05 | INDV | Indivior Plc | Humphreys Keith | Dir | P - Purchase | $35.39 | +775 | 5,802 | +15% | +$27,429 | ||||||
2026-01-05 | INDV | Indivior Plc | Ninivaggi Daniel A | Dir | P - Purchase | $35.39 | +775 | 16,923 | +5% | +$27,429 | ||||||
2026-01-05 | INDV | Indivior Plc | Stejbach Mark | Dir | P - Purchase | $35.39 | +775 | 16,847 | +5% | +$27,429 | ||||||
2026-01-05 | INDV | Indivior Plc | Wheadon David E. | Dir | P - Purchase | $35.39 | +1,771 | 14,395 | +14% | +$62,680 | ||||||
2026-01-05 | ACTU | Actuate Therapeutics, Inc. | Thomson Todd S | Dir, 10% | S - Sale | $5.80 | -280,000 | 2,354,344 | -11% | -$1,624,000 | ||||||
2026-01-02 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO | S - Sale | $30.68 | -15,000 | 671,907 | -2% | -$460,134 | ||||||
| D | 2026-01-02 | WVE | Wave Life Sciences Ltd. | Francis Chris | See Remarks | S - Sale+OE | $16.03 | -9,375 | 25,000 | -27% | -$150,260 | |||||
| D | 2026-01-05 | ANAB | Anaptysbio, Inc | Faga Daniel | Pres, CEO | S - Sale+OE | $43.26 | -15,309 | 458,139 | -3% | -$662,267 | |||||
| D | 2026-01-05 | ANAB | Anaptysbio, Inc | Mulroy Dennis | CFO | S - Sale+OE | $43.26 | -3,363 | 14,330 | -19% | -$145,483 | |||||
| D | 2026-01-05 | ANAB | Anaptysbio, Inc | Lizzul Paul F. | Chief Medical Officer | S - Sale+OE | $43.26 | -4,219 | 33,303 | -11% | -$182,514 | |||||
| D | 2026-01-05 | ANAB | Anaptysbio, Inc | Loumeau Eric J | GC | S - Sale+OE | $43.26 | -2,983 | 13,251 | -18% | -$129,045 | |||||
| D | 2026-01-05 | TERN | Terns Pharmaceuticals, Inc. | Burroughs Amy L. | CEO | S - Sale+OE | $38.10 | -71,339 | 147,295 | -33% | -$2,718,230 | |||||
2026-01-02 | TERN | Terns Pharmaceuticals, Inc. | Kuriakose Emil | Chief Medical Officer | S - Sale | $38.57 | -1,155 | 50,365 | -2% | -$44,552 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |